Edition:
United States

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

29.13USD
23 Apr 2018
Change (% chg)

$0.23 (+0.80%)
Prev Close
$28.90
Open
$28.87
Day's High
$29.33
Day's Low
$28.86
Volume
231,760
Avg. Vol
299,556
52-wk High
$41.52
52-wk Low
$17.73

Chart for

About

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $2,018.67
Shares Outstanding(Mil.): 69.85
Dividend: --
Yield (%): --

Financials

  MYGN.OQ Industry Sector
P/E (TTM): 15.80 33.30 32.78
EPS (TTM): 1.84 -- --
ROI: 11.49 9.89 13.21
ROE: 15.81 14.71 15.01

BRIEF-Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan

April 2 Myriad Genetics Inc - ‍Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :

Apr 02 2018

BRIEF-Myriad Genetics Q2 Adjusted Earnings Per Share $0.31

* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2018 FINANCIAL RESULTS

Feb 06 2018

UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

Jan 12 2018

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results

Nov 07 2017

BRIEF-Myriad announces GeneSight Psychotropic results from a large prospective trial in patients with major depressive disorder

* Myriad announces GeneSight® Psychotropic results from a large prospective trial in patients with major depressive disorder

Nov 02 2017

BRIEF-‍Myriad Genetics announces new positive results for EndoPredict

* Endopredict (epclin) shown in second study to be more effective than oncotype dx® (rs) in women with intermediate risk of breast cancer recurrence

Oct 26 2017

Competitors

Earnings vs. Estimates